Journal of nuclear medicine technology最新文献

{"title":"De Novo Small Cell Neuroendocrine Carcinoma of the Prostate: Molecular Heterogeneity on Triple-Tracer PET/CT and Its Implications for Personalized Treatment Strategy.","authors":"Rangat Bagasariya, Rahul Vithalrao Parghane, Sandip Basu","doi":"10.2967/jnmt.126.272275","DOIUrl":"https://doi.org/10.2967/jnmt.126.272275","url":null,"abstract":"<p><p>De novo small cell neuroendocrine carcinoma of the prostate is a rare, aggressive malignancy with heterogeneous molecular characteristics. We report the case of a patient with metastatic prostatic small cell neuroendocrine carcinoma that showed variable tracer avidity on triple-tracer PET/CT ([¹⁸F]FDG, [⁶⁸Ga]Ga-DOTATATE, and [⁶⁸Ga]Ga-PSMA-11). All lesions demonstrated intense [¹⁸F]FDG avidity, reflecting dedifferentiated biology. In contrast, [⁶⁸Ga]Ga-DOTATATE PET/CT showed uptake in only half of the lesions, predominantly in infradiaphragmatic lesions, whereas there was no uptake of [⁶⁸Ga]Ga-PSMA-11 PET/CT across all lesions. This striking discordance highlights the complementary role of triple-tracer PET/CT in characterizing tumor heterogeneity, accurate staging, and planning personalized imaging and therapeutic strategies in such aggressive malignancies.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Considerations for Prostate Cancer Imaging and Radiopharmaceutical Therapy.","authors":"Victoria West, Phillip Morse, Mike Nguyen, Celeste Winters, Erik Mittra","doi":"10.2967/jnmt.126.272276","DOIUrl":"10.2967/jnmt.126.272276","url":null,"abstract":"<p><p>Prostate cancer is a rapidly expanding area for radiopharmaceutical therapy, primarily driven by prostate-specific membrane antigen-targeted imaging and therapy. This growth necessitates new workflows that address the full clinical spectrum of care. This article describes a practice-based approach that follows the prostate cancer patient's course through this therapy, from referral, imaging, consultation, and therapy administration. Key operational components are reviewed, including radiopharmaceutical selection, imaging options, scheduling, staffing considerations, radiation safety, and therapy delivery methods. Common challenges and practical solutions are highlighted. Together, this work supports the radiopharmaceutical therapy care team in delivering coordinated, high-quality care across the diagnostic and therapeutic phases of prostate cancer management.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"153-157"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Imaging-PET: ⁶⁸Ga-Gozetotide (Locametz, Illuccix, and Gozellix).","authors":"Victoria West, Mary Beth Farrell, Kathy S Thomas, Eleanor S Mantel, Jessica Settle","doi":"10.2967/jnmt.126.272484","DOIUrl":"10.2967/jnmt.126.272484","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"158-159"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Imaging-PET: ¹⁸F-Piflufolastat (Pylarify).","authors":"Victoria West, Mary Beth Farrell, Kathy S Thomas, Eleanor S Mantel, Jessica Settle","doi":"10.2967/jnmt.126.272487","DOIUrl":"10.2967/jnmt.126.272487","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"160-161"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer: ¹⁷⁷Lu-PSMA (Pluvicto).","authors":"Mary Beth Farrell, Kathy S Thomas, Eleanor S Mantel, Jessica Settle","doi":"10.2967/jnmt.126.272485","DOIUrl":"10.2967/jnmt.126.272485","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"166-167"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer, Part 1: Contemporary Radioligands.","authors":"Geoffrey M Currie, Eric M Rohren","doi":"10.2967/jnmt.125.271978","DOIUrl":"10.2967/jnmt.125.271978","url":null,"abstract":"<p><p>Prostate cancer is one of the most prevalent malignancies in men and remains a leading cause of cancer-related morbidity and mortality worldwide. For many, prostate cancer follows an indolent course, while others demonstrate aggressive biologic behavior. This highlights the importance of early detection, accurate staging, and biologically informed treatment selection. Nuclear medicine plays a central role in the contemporary management of prostate cancer, providing molecular insights that extend beyond anatomy to interrogate tumor metabolism, proliferation, hypoxia, stromal interactions, and receptor expression. These biologic dimensions are the foundation of both diagnostic imaging and targeted radionuclide therapy. This article provides a biologically structured overview of contemporary non-prostate-specific membrane antigen (PSMA) radiopharmaceuticals used in prostate cancer imaging and therapy, emphasizing the molecular and cellular mechanisms that determine their suitability for diagnostic, therapeutic, or theranostic application. Key determinants of radioligand performance are explored, including physical radionuclide properties, radiochemical stability, molecular internalization and retention, and pharmacologic biodistribution. These factors explain why imaging and therapeutic ligands, although conceptually linked, are not interchangeable and must be carefully matched to biologic behavior and clinical intent. Major biologic imaging pathways relevant to prostate cancer, including glycolytic metabolism, hypoxia, lipid and phospholipid synthesis, amino acid transport and protein synthesis, nucleoside metabolism, androgen receptor signaling, fibroblast activation protein targeting, and skeletal metastasis imaging are reviewed. For each pathway, the molecular rationale for tracer uptake, strengths, and limitations in prostate cancer phenotypes and implications for prognosis and therapy selection are outlined. Importantly, prostate cancer is not a single-pathway disease. Tumor heterogeneity, metabolic plasticity, and microenvironmental adaptation, particularly in castration-resistant disease, necessitate a broader molecular imaging perspective beyond PSMA alone. Although PSMA-targeted imaging and therapy have become clinical mainstays, non-PSMA radioligands retain critical complementary roles in selected clinical scenarios, translational research, and therapy development. This article provides a biologically grounded framework for understanding contemporary prostate cancer radioligands and establishes the foundation for part 2 of this series, which will focus on PSMA-based and emerging molecular strategies shaping the future of prostate cancer theranostics.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"127-135"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer, Part 2: PSMA and Beyond.","authors":"Geoffrey M Currie, Eric M Rohren","doi":"10.2967/jnmt.125.271979","DOIUrl":"10.2967/jnmt.125.271979","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) has fundamentally reshaped prostate cancer imaging and therapy, delivering an unprecedented combination of high lesion conspicuity, broad clinical applicability, and direct theranostic linkage between molecular imaging and radionuclide treatment. Building on the broader non-PSMA radioligand landscape reviewed in part 1, this companion article focuses on PSMA biology, the mechanistic basis for PSMA radiopharmaceutical performance, and emerging molecular strategies that address heterogeneity, treatment resistance, and access constraints. This article summarizes contemporary PSMA PET agents and PSMA-directed radioligand therapy, highlighting how chelator chemistry, linker design, and accessory binding sites influence pharmacokinetics, affinity, internalization, and suitability for imaging versus therapy. β-emitting therapy with ¹⁷⁷Lu-PSMA-617 is supported by high-level evidence and regulatory approvals, demonstrating improved progression-free and overall survival in metastatic castration-resistant prostate cancer. In parallel, α-emitting strategies such as ²²⁵Ac-PSMA exploit high linear energy transfer and short path length to treat micrometastatic and radioresistant disease, including post-β-therapy progression, but are constrained by toxicity risk, daughter redistribution, complex dosimetry, and limited radionuclide supply. Emerging radionuclides and ligand-engineering approaches are discussed as routes to improve tumor retention, enable true theranostic pairing, and expand global feasibility. The next wave of strategies that broaden molecular coverage beyond PSMA alone, including gastrin-releasing peptide receptor- and fibroblast activation protein-targeted agents and dual-target heterodimers, designed to address inter- and intrapatient heterogeneity and PSMA-insufficient disease, are also outlined. These advances shift prostate cancer theranostics from a single-target paradigm toward a more nuanced ecosystem requiring rational selection, sequencing, and personalization of radioligand choice across the disease continuum.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"136-143"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Imaging-PET: ¹⁸F-Fluciclovine (Axumin).","authors":"Mary Beth Farrell, Kathy S Thomas, Eleanor S Mantel, Jessica Settle","doi":"10.2967/jnmt.126.272483","DOIUrl":"10.2967/jnmt.126.272483","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"164-165"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Year of Growth, Change, and Momentum.","authors":"Cybil J Nielsen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"54 2","pages":"7A-8A"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer: Staging, Progression, and Treatment.","authors":"Nicole LaBrecque, Alexia Romano, Jared LeBlanc, David Gilmore","doi":"10.2967/jnmt.126.272212","DOIUrl":"10.2967/jnmt.126.272212","url":null,"abstract":"<p><p>Although prostate cancer has traditionally been regarded as a disease of older men, emerging evidence suggests a shift toward diagnosis at younger ages. Increased prostate-specific antigen screening has been proposed as a contributing factor to the rising rate of prostate cancer in younger men. There is no single laboratory test that can conclude a prostate cancer diagnosis; however, there is evidence that a higher prostate-specific antigen level can signify a higher likelihood of prostate cancer. Treatment of prostate cancer is dependent on disease stage, risk category, symptoms, age, comorbidities, and patient preferences; thus, management of the disease can vary. When discussing cancer, especially prostate cancer, staging is a vital step in the diagnosis and evaluation of the disease. Imaging and assessment tools used in the staging process of a prostate cancer diagnosis and treatment management include CT, MRI, nuclear medicine bone scans, PSMA PET/CT, and Gleason score assessment.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"54 2","pages":"121-126"},"PeriodicalIF":1.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}